Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C. et al, (2013), Lancet Oncol, 14, 733 - 740
Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.
Corrie P. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
A phase I study of oral rucaparib in combination with carboplatin.
Molife LR. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.
Corrw P. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
Gupta A. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma.
Ahmad S. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma
Middleton MR. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Phase II trial of nemorubicin hydrochloride (N) in combination with cisplatin (cDDP) administered by intra-hepatic artery (IHA) in patients (pts) with hepatocellular carcinoma (HCC): Final results.
Izzo F. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Safety, pharmacokinetics, and preliminary activity of the alpha-specific PI3K inhibitor BYL719: Results from the first-in-human study.
Gonzalez-Angulo AM. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.
Lu M. et al, (2013), Cancer Cell, 23, 618 - 633
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Plummer R. et al, (2013), Cancer Chemother Pharmacol, 71, 1191 - 1199
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.
Ong CC. et al, (2013), J Natl Cancer Inst, 105, 606 - 607
IMCgp100: a novel bispecific biologic for the treatment of malignant melanoma.
Middleton M. et al, (2013), CANCER RESEARCH, 73
Melanoma in buckinghamshire: data from the inception of the skin cancer multidisciplinary team.
Cubitt JJ. et al, (2013), J Skin Cancer, 2013
New treatment approaches in melanoma: current research and clinical prospects.
Rughani MG. et al, (2013), Ther Adv Med Oncol, 5, 73 - 80
Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors
Bahleda R. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 75 - 75
Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study).
Lebbe C. et al, (2012), Eur J Cancer, 48, 3205 - 3214
Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study)
Lebbe C. et al, (2012), European Journal of Cancer, 48, 3205 - 3214
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus.
Su Z. et al, (2012), Nat Genet, 44, 1131 - 1136